ArticleProstate cancer and prostatic diseases2013
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.
Article in Prostate cancer and prostatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 67 citations in OpenAlex.
- Early-Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection.MedComm · 2026Review
- PTEN and ERG Biomarkers as Predictors of Biochemical Recurrence Risk in Patients Undergoing Radical Prostatectomy.Diseases (Basel, Switzerland) · 2025Article
- Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.Virchows Archiv : an international journal of pathology · 2024Article
- Germline determinants of aberrant signaling pathways in cancer.NPJ precision oncology · 2024Article
- Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer.Cancer medicine · 2023Article
- The evolving landscape of prostate cancer somatic mutations.The Prostate · 2022Review
- Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.Prostate cancer and prostatic diseases · 2021Article
- microRNA Expression Profiling in Young Prostate Cancer Patients.Journal of Cancer · 2020Article
- Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifiesOncotarget · 2019Article
- Article
- Ethnicity and ERG frequency in prostate cancer.Nature reviews. Urology · 2018Review
- SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.The Journal of clinical investigation · 2018Article
- Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.JCO precision oncology · 2018Article
- Deletion of 3p13 is a late event linked to progression ofCancer management and research · 2018Article
- Predictive significance ofCancer cell international · 2018Review
- The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature.Frontiers in oncology · 2018Article
- Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics.Virchows Archiv : an international journal of pathology · 2017Article
- Inherited determinants of early recurrent somatic mutations in prostate cancer.Nature communications · 2017Article
- Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.Open access Macedonian journal of medical sciences · 2017Article
- The Use of Biomarkers in Prostate Cancer Screening and Treatment.Reviews in urology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundThe TMPRSS2-ERG gene fusion resulting in ERG overexpression has been found in around 50% of prostate cancers (PCa) and is a very early event in tumorigenesis. Most studies have reported on selected surgical cohorts with inconsistent results. We hypothesized that ERG gene rearrangements impact tumor development and investigated the frequency of ERG overexpression in the context of clinicopathological tumor characteristics.
methodsERG overexpression (ERG+ or ERG-) was determined by immunohistochemistry (IHC) in 1039 radical prostatectomy (RP) tumors and association with PSA, D'Amico risk score, histopathology, biochemical recurrence, body mass index and age of PCa cases was analyzed.
resultsERG+ was associated with younger age at diagnosis (P<0.0001), lower serum PSA (P=0.002) and lower prostate volume (PV) (P=0.001). It was most frequent in the youngest age quartile (≤55 years, 63.9% ERG+) and decreased constantly with increasing age to 40.8% in the oldest age quartile (≥67 years, P<0.0001). In the PSA range <4 ng ml(-1) the frequency of ERG positivity was 60.2% compared with 47.5 and 49.1% in the PSA ranges 4-10 and ≥10 ng ml(-1), respectively. In the first age quartile, ERG+ patients had lower median serum PSA and fPSA% and smaller PV. In the highest age quartile tumor volume (TV) was increased. Similar differences were observed in the low PSA range. Multivariate analysis identified the first age quartile as a predictor for ERG status (odds ratios (OR) 2.05, P=0.007). No association was found with the D'Amico progression risk score and with biochemical tumor recurrence.
conclusionsERG+ tumors manifest clinically at lower PSA levels and their prevalence is age dependent. This suggests acceleration of tumor development by ERG overexpression that results in earlier tumor detection in young patients. Long-term results are warranted to determine the impact of ERG overexpression on disease outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.